Form 4: Corcept Therapeutics Executive Gary Robb Reports Stock Transactions

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports acquiring and disposing of company stock, including shares withheld for tax obligations and purchases under an incentive plan.

Summary

• Gary Robb, the Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On June 3, 2024, 724 shares were withheld to cover tax obligations at a price of $30.17 per share.
• On the same day, Robb acquired 1,818 shares at $31.30 per share through a purchase plan and another 1,818 shares as unvested restricted stock awards.
• Following these transactions, Robb directly owns 23,115 shares and indirectly owns 25,100 shares through custodial accounts for his children.
• The filing also notes that some shares are subject to vesting requirements based on continued ownership and employment.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The transactions themselves don't necessarily indicate positive or negative sentiment, but the executive's purchase could be interpreted as a slightly positive signal.

Positives

• The purchase of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but it does mention vesting schedules for restricted stock awards, contingent on continued employment and ownership.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their executives. They provide transparency into insider transactions, which can be informative for investors.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Vesting schedules for restricted stock awards are a common practice to incentivize long-term commitment.
• Similar filings are made by executives at comparable pharmaceutical companies like AbbVie, Eli Lilly, and Pfizer, detailing their stock transactions.

Stakeholder Impact

• Shareholders may view the executive's stock purchase as a positive sign of confidence in the company.
• The withholding of shares for tax obligations has a neutral impact on stakeholders.

Key Dates